Denosumab

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologic medicines to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturi...

 BlincytoCLD initiated

BlincytoNMPA IND approved, process at 50Lscale

We offer efficient, flexible and high performing mammalian cell line development to transform your research into drug substances

Leveraging the internal expression vector engineering expertise, we have optimized and engineered the proprietary vectors with selection stringency to be used with our...

Strict enforcement to protect our client’s confidential information is our top priority at Chime Biologics  We conduct regular and intense employee compliance training with particular focus on IP protection programs.

Our abiding commitment to confidentiality warrant us as your reliable part...

Chime Biologics has upgraded its IT infrastructure and adopted a series of computerized systems to ensure highest degree of data authenticity, completeness and accuracy. All computerized systems have been validated as per global regulatory requirements to assure that accurate, consistent and reliable resul...

Prolia Phase I completion

Liquid fill (2mL, 6mL, 10 mL, 15 mL, 20 mL, 50mL) with a state-of-art imported filling line and 100% online weigh check.
Lyophilization fill (2mL, 10mL, 20mL) with fully automated loading/unloading, a 25 m2 lyophilizer and 100% online weigh check.


Pre-filled syringe fill (1mL, 2.25mL) wi...

We deliver scalable biomanufacturing solutions with bioreactors from 50L to 2000L, enabling flexible capacity adjustment for projects at all development stages.All bioreactors and preparation tanks adopt single-use systems, cutting cleaning, sterilization and maintenance costs and time, shortening producti...

DupixentPD ongoing

lmfinziCLD initiated

OriginatorBrand HemlibraNMPA IND approved, process at 500Lscale

Frédéric Bouvier is a senior biopharmaceutical executive with 25+ years of experience in biologics and biosimilars across Sanofi, Fresenius Kabi, biotech startups, and CDMO organizations. His expertise spans corporate strategy, business development, portfolio build-up, and commercialization, with a strong track record of bringing biosimilars to international markets.

In this interview, Peter Pang discusses evolving risks and key considerations for biosimilar CMC amid the growing adoption of CES waivers by regulators.

A prefilled syringe (PFS) is a ready-to-use disposable syringe with a premeasured dose, eliminating the need to draw medication from a vial.

March 2026, Shanghai, China — Chime Biologics, a leading global CDMO that enables its partners' success in biologics, congratulates its partner Hope Medicine Inc. on the successful dosing of the first patient in the Phase III clinical trial of HMI-115, a novel monoclonal antibody developed for the treatment of endometriosis. This milestone was achieved at the lead site, Peking Union Medical College Hospital, in China. The trial is a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the safety and efficacy of HMI-115 in treating moderate to severe pain associated with endometriosis.

Recently, the 2026 Hubei–Korea Future Cooperation Exchange Event was successfully held in Wuhan, China. As an important platform for efficient collaboration between Chinese and Korean industries and capital, the event brought together government agencies, financial institutions, well-known enterprises, and industry representatives from both countries to conduct in-depth exchanges on strategic emerging industries, with a focus on biomedicine.

At this year’s BIO Equity Europe discussions held in Prague, Czech Republic earlier this month, one message resonated consistently across presentations, panels, and investor conversations: the global biotechnology industry is entering a new era defined by artificial intelligence, accelerated innovation efficiency, and strategic global collaboration.

Representing Chime Biologics, Board Director and CEO Jimmy Wei shared the company’s vision in a featured presentation titled “Turning AI into Biologics Reality”, highlighting how Chime Biologics is integrating China’s rapidly advancing AI ecosystem into end-to-end biologics development and manufacturing capabilities.

Wuhan, China & Seoul, South Korea | June 2, 2026 — Chime Biologics, a global biologics CDMO dedicated to enabling partners’ success, and Daewoong Pharmaceutical, a leading South Korean pharmaceutical company, today announced the signing of a strategic partnership agreement for the development and manufacturing of a dupilumab biosimilar candidate referencing Dupixent.